Reduction in serum cholesterol with pravastatin improves endothelium- dependent coronary vasomotion in patients with hypercholesterolemia

Kensuke Egashira, Yoshitaka Hirooka, H. Kai, M. Sugimachi, S. Suzuki, T. Inou, A. Takeshita

Research output: Contribution to journalArticle

607 Citations (Scopus)

Abstract

Background: This study aimed to determine if cholesterol-lowering therapy improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Methods and Results: Nine patients with hypercholesterolemia were studied before and after cholesterol-lowering therapy with pravastatin (an inhibitor of HMG-CoA reductase) for 6±3 months, which lowered serum cholesterol from 272±8 to 187±16 mg/dL (P<.01). Control patients with serum cholesterol of 218±23 mg/dL also were studied twice in a similar interval (8±2 months) with no cholesterol-lowering drugs. Acetylcholine (the endothelium-dependent vasodilator) and papaverine and nitrate (endothelium-independent vasodilators) were infused into the study coronary artery. Changes in the diameter of the epicardial coronary artery and coronary blood flow were assessed by quantitative coronary arteriography and an intracoronary Doppler catheter. In patients with hypercholesterolemia, acetylcholine-induced vasoconstriction of the epicardial artery was less (P<.05) and the acetylcholine-induced increases in coronary blood flow were greater (P<.001) after than before pravastatin. In control patients, responses of the epicardial coronary artery and coronary blood flow to acetylcholine did not change over the follow-up period. The vasomotor responses to papaverine or nitrate were similar between the two groups, and no interval changes in their responses were noted in either group. Conclusions: These results suggest that cholesterol-lowering therapy with pravastatin may improve endothelium-dependent coronary vasomotion, which may possibly contribute to the improvement of myocardial perfusion as well as the regression of coronary atherosclerosis.

Original languageEnglish
Pages (from-to)2519-2524
Number of pages6
JournalCirculation
Volume89
Issue number6
DOIs
Publication statusPublished - Jan 1 1994

Fingerprint

Pravastatin
Hypercholesterolemia
Endothelium
Cholesterol
Acetylcholine
Serum
Coronary Vessels
Papaverine
Nitrates
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Endothelium-Dependent Relaxing Factors
Vasoconstriction
Vasodilator Agents
Coronary Artery Disease
Angiography
Therapeutics
Catheters
Arteries
Perfusion
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Reduction in serum cholesterol with pravastatin improves endothelium- dependent coronary vasomotion in patients with hypercholesterolemia. / Egashira, Kensuke; Hirooka, Yoshitaka; Kai, H.; Sugimachi, M.; Suzuki, S.; Inou, T.; Takeshita, A.

In: Circulation, Vol. 89, No. 6, 01.01.1994, p. 2519-2524.

Research output: Contribution to journalArticle

Egashira, Kensuke ; Hirooka, Yoshitaka ; Kai, H. ; Sugimachi, M. ; Suzuki, S. ; Inou, T. ; Takeshita, A. / Reduction in serum cholesterol with pravastatin improves endothelium- dependent coronary vasomotion in patients with hypercholesterolemia. In: Circulation. 1994 ; Vol. 89, No. 6. pp. 2519-2524.
@article{8ede4571cae0485f9af822a17d373afd,
title = "Reduction in serum cholesterol with pravastatin improves endothelium- dependent coronary vasomotion in patients with hypercholesterolemia",
abstract = "Background: This study aimed to determine if cholesterol-lowering therapy improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Methods and Results: Nine patients with hypercholesterolemia were studied before and after cholesterol-lowering therapy with pravastatin (an inhibitor of HMG-CoA reductase) for 6±3 months, which lowered serum cholesterol from 272±8 to 187±16 mg/dL (P<.01). Control patients with serum cholesterol of 218±23 mg/dL also were studied twice in a similar interval (8±2 months) with no cholesterol-lowering drugs. Acetylcholine (the endothelium-dependent vasodilator) and papaverine and nitrate (endothelium-independent vasodilators) were infused into the study coronary artery. Changes in the diameter of the epicardial coronary artery and coronary blood flow were assessed by quantitative coronary arteriography and an intracoronary Doppler catheter. In patients with hypercholesterolemia, acetylcholine-induced vasoconstriction of the epicardial artery was less (P<.05) and the acetylcholine-induced increases in coronary blood flow were greater (P<.001) after than before pravastatin. In control patients, responses of the epicardial coronary artery and coronary blood flow to acetylcholine did not change over the follow-up period. The vasomotor responses to papaverine or nitrate were similar between the two groups, and no interval changes in their responses were noted in either group. Conclusions: These results suggest that cholesterol-lowering therapy with pravastatin may improve endothelium-dependent coronary vasomotion, which may possibly contribute to the improvement of myocardial perfusion as well as the regression of coronary atherosclerosis.",
author = "Kensuke Egashira and Yoshitaka Hirooka and H. Kai and M. Sugimachi and S. Suzuki and T. Inou and A. Takeshita",
year = "1994",
month = "1",
day = "1",
doi = "10.1161/01.CIR.89.6.2519",
language = "English",
volume = "89",
pages = "2519--2524",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Reduction in serum cholesterol with pravastatin improves endothelium- dependent coronary vasomotion in patients with hypercholesterolemia

AU - Egashira, Kensuke

AU - Hirooka, Yoshitaka

AU - Kai, H.

AU - Sugimachi, M.

AU - Suzuki, S.

AU - Inou, T.

AU - Takeshita, A.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Background: This study aimed to determine if cholesterol-lowering therapy improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Methods and Results: Nine patients with hypercholesterolemia were studied before and after cholesterol-lowering therapy with pravastatin (an inhibitor of HMG-CoA reductase) for 6±3 months, which lowered serum cholesterol from 272±8 to 187±16 mg/dL (P<.01). Control patients with serum cholesterol of 218±23 mg/dL also were studied twice in a similar interval (8±2 months) with no cholesterol-lowering drugs. Acetylcholine (the endothelium-dependent vasodilator) and papaverine and nitrate (endothelium-independent vasodilators) were infused into the study coronary artery. Changes in the diameter of the epicardial coronary artery and coronary blood flow were assessed by quantitative coronary arteriography and an intracoronary Doppler catheter. In patients with hypercholesterolemia, acetylcholine-induced vasoconstriction of the epicardial artery was less (P<.05) and the acetylcholine-induced increases in coronary blood flow were greater (P<.001) after than before pravastatin. In control patients, responses of the epicardial coronary artery and coronary blood flow to acetylcholine did not change over the follow-up period. The vasomotor responses to papaverine or nitrate were similar between the two groups, and no interval changes in their responses were noted in either group. Conclusions: These results suggest that cholesterol-lowering therapy with pravastatin may improve endothelium-dependent coronary vasomotion, which may possibly contribute to the improvement of myocardial perfusion as well as the regression of coronary atherosclerosis.

AB - Background: This study aimed to determine if cholesterol-lowering therapy improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Methods and Results: Nine patients with hypercholesterolemia were studied before and after cholesterol-lowering therapy with pravastatin (an inhibitor of HMG-CoA reductase) for 6±3 months, which lowered serum cholesterol from 272±8 to 187±16 mg/dL (P<.01). Control patients with serum cholesterol of 218±23 mg/dL also were studied twice in a similar interval (8±2 months) with no cholesterol-lowering drugs. Acetylcholine (the endothelium-dependent vasodilator) and papaverine and nitrate (endothelium-independent vasodilators) were infused into the study coronary artery. Changes in the diameter of the epicardial coronary artery and coronary blood flow were assessed by quantitative coronary arteriography and an intracoronary Doppler catheter. In patients with hypercholesterolemia, acetylcholine-induced vasoconstriction of the epicardial artery was less (P<.05) and the acetylcholine-induced increases in coronary blood flow were greater (P<.001) after than before pravastatin. In control patients, responses of the epicardial coronary artery and coronary blood flow to acetylcholine did not change over the follow-up period. The vasomotor responses to papaverine or nitrate were similar between the two groups, and no interval changes in their responses were noted in either group. Conclusions: These results suggest that cholesterol-lowering therapy with pravastatin may improve endothelium-dependent coronary vasomotion, which may possibly contribute to the improvement of myocardial perfusion as well as the regression of coronary atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0028283817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028283817&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.89.6.2519

DO - 10.1161/01.CIR.89.6.2519

M3 - Article

VL - 89

SP - 2519

EP - 2524

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6

ER -